Expession Of PSMD10 In Human Ovarian Cancer Cells Inhibited By Salidroside

Research background:Ovarian cancer is a common gynecological malignancy.Because early clinical symptoms of ovarian cancer is not obvious,so early ovarian cancer patients are not easy to detect.Approximately 75%of patients with ovarian cancer are diagnosed with advanced or metastatic ovarian cancer and even spread throughout the peritoneum,liver parenchyma,or pleura.The mortality rate of ovarian cancer is the first in gynecologic malignancies.The recurrence and metastasis of patients with 80%-90%in a short time will lead to a high recurrence rate and mortality of ovarian cancer.The 5 year survival rate is only about 25%to 30%.Therefore,in order to improve the 5 year survival rate of ovarian cancer,we should do early diagnosis and targeted treatment.At present,the pathogenesis of ovarian cancer is not clear,including genetic factors,environmental factors,reproductive factors and behavioral factors,etc..Therefore,the in-depth study of the pathogenesis and targeted therapy for ovarian cancer is particularly importantObjective:This study was conducted in two aspects.The first part was to investigate the expression of PSMD10 in peripheral blood of patients with epithelial ovarian cancer.PSMD10 has been found to be highly expressed in the tissues of patients with ovarian cancer.In order to find a more convenient method of detection,we tried to study the peripheral blood of ovarian cancer.In the second part,we studied the effect of Rhodiola rosea on the inhibition of PSMD10 in human ovarian cancer cell line SKOV3,which has an inhibitory effect on ovarian cancer cell line SKOV3.The aim was to provide theoretical basis for further study on the killing mechanism of salidroside on human ovarian cells.Methods:The first part are the peripheral blood samples from 80 patients with epithelial ovarian cancer and the peripheral blood samples from 30 patients with gynecological malignancies which are selected from June 2016 to January 2017 in the Third Affiliated Hospital of Harbin Medical University Department of hospital,and all the patients were diagnosed by histology.In patients with epithelial ovarian cancer,there were 30 patients with primary ovarian cancer,and 20 patients with recurrent ovarian cancer,and 30 patients with postoperative ovarian cancer.We used ELISA to detect the amount of PSMD10 in the peripheral blood of the collected patients.In the second part,PSMD10 antibodies were separately added to human ovarian cancer cell line SKOV3 and salidroside inhibited human ovarian cancer cell line SKOV3.Western bolt method was used to detect the expression of PSMD10 in two groups of human ovarian cells.Results:1.The concentration expression of-PSMD10 in the peripheral blood of patients with recurrent ovarian cancer was higher than that in the patients with primary ovarian cancer,and there was significant difference between the two groups(P<0.01).2.The concentration expression of PSMD10 in the peripheral blood of patients with recurrent ovarian cancer was higher than that of the patients with ovarian cancer after chemotherapy,and the difference between the two groups was statistically significant(P<0.01).3.The concentration expression of PSMD10 in the peripheral blood of patients with primary ovarian cancer group was higher than that of the patients with ovarian cancer after chemotherapy,the difference between the two groups was statistically significant(P<0.01).4.The content of PSMD10 in peripheral blood of patients with primary ovarian cancer was higher than that of other gynecological malignant tumors.There was significant difference between the two groups(P<0.01).5.The expression of PSMD10 in peripheral blood of patients with epithelial ovarian cancer is specific,and the specificity was the most obvious in the recurrent ovarian cancer group,and the strong positive rate was 85%.There was no significant difference in PSMD10 in other gynecological malignant tumors.6.The expression of PSMD10 in human ovarian cancer cell line SKOV3 was increased and decreased in the human ovarian cancer cell line SKOV3.Conclusion:1.In the peripheral blood of patients with epithelial ovarian cancer,the expression of PSMD10 in the relapse group was significantly specific,and the expression concentration of PSMD10 in the primary group was significantly increased.2.In the peripheral blood of patients with epithelial ovarian cancer,the expression of PSMD10 in the postoperative group was decreased and the therapeutic effect was obvious.3.The expression of PSMD10 in peripheral blood of patients with epithelial ovarian cancer was significantly specific,but the expression of PSMD 10 in peripheral blood of other gynecological malignancies was not specific.4.Salidroside may inhibit the expression of PSMD10 through some target or pathway.